Trabectedin
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Trabectedin |
| DrugBank ID | DB05109 |
| Brand Names (EU) | Yondelis |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.73% |
Approved Indication (EMA)
Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | female breast carcinoma | 99.73% | DL |
| 2 | hereditary breast ovarian cancer syndrome | 99.51% | DL |
| 3 | ovarian clear cell adenocarcinoma | 99.35% | DL |
| 4 | malignant dysgerminomatous germ cell tumor of ovary | 99.22% | DL |
| 5 | borderline epithelial tumor of ovary | 99.18% | DL |
| 6 | hereditary site-specific ovarian cancer syndrome | 99.09% | DL |
| 7 | malignant sex cord stromal tumor of ovary | 98.98% | DL |
| 8 | familial ovarian cancer | 98.97% | DL |
| 9 | choriocarcinoma of ovary | 98.94% | DL |
| 10 | gonadal germ cell tumor | 98.92% | DL |
| 11 | ovarian primitive germ cell tumor | 98.91% | DL |
| 12 | maligant granulosa cell tumor of ovary | 98.73% | DL |
| 13 | ovarian malignant mesothelioma | 98.63% | DL |
| 14 | malignant non-dysgerminomatous germ cell tumor of ovary | 98.62% | DL |
| 15 | malignant germ cell tumor of ovary | 98.62% | DL |
| 16 | yolk sac tumor | 98.60% | DL |
| 17 | ovarian adenosarcoma | 98.50% | DL |
| 18 | ovarian cancer, susceptibility to, 1 | 98.50% | DL |
| 19 | ovarian Sertoli-Leydig cell tumor | 98.47% | DL |
| 20 | ovarian thecoma | 98.46% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.